Transplant Diagnostics Market worth $8.14 billion by 2031
The report "Transplant Diagnostics Market by Product & Service (Instrument, Software), Technology (PCR, NGS), Application [Diagnostic (Infectious Disease, HLA) Research], Type [Solid Organ (Heart), Bone Marrow], End User (Hospital) & Region -Global Forecast to 2031", is projected to grow from USD 5.61 billion in 2026 and to reach USD 8.14 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period.
Browse 500 market data Tables and 50 Figures spread through 499 Pages and in-depth TOC on "Transplant Diagnostics Market by Product & Service (Instrument, Software), Technology (PCR, NGS), Application [Diagnostic (Infectious Disease, HLA) Research], Type [Solid Organ (Heart), Bone Marrow], End User (Hospital) & Region -Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/global-transplant-diagnostics-market-2531061.html
The transplant diagnostics market is experiencing steady growth, primarily driven by the increasing number of organ transplant procedures worldwide. The rising incidence of chronic diseases that lead to organ failure, combined with greater awareness of organ donation and transplantation, is boosting the demand for accurate donor-recipient compatibility testing. Additionally, advancements in molecular diagnostic technologies, such as PCR and next-generation sequencing (NGS), are enhancing the accuracy and efficiency of transplant diagnostics. The growing public and private funding for transplant research, along with the increasing adoption of cross-matching and chimerism testing, further supports market growth. However, the high cost of advanced molecular diagnostic techniques and limited access to sophisticated transplant diagnostic infrastructure in emerging economies may, to some extent, restrict market growth.
By technology, the molecular assays segment accounted for the largest share of the transplant diagnostics market in 2025.
The transplant diagnostics market is divided into two main technology categories: molecular and non-molecular assays. The molecular assays segment is further classified into two subcategories: PCR-based and sequencing-based assays. PCR-based molecular assays include real-time PCR, SSP-PCR, SSO-PCR, and related methods. Meanwhile, sequencing-based molecular assays encompass Sanger sequencing, next-generation sequencing (NGS), and additional sequencing techniques. In 2025, the molecular assay segment dominated the transplant diagnostics market. This growth is primarily driven by the advantages that molecular assays offer over non-molecular assays. These advantages include shorter turnaround times, higher procedural efficacy, the capability to analyze multiple samples simultaneously, and real-time sample analysis. Additionally, factors such as increased applications in patient profiling, rising public and private investments in product development, growing clinical evidence supporting the efficacy of molecular assay techniques, and ongoing technological advancements are contributing to the expansion of this segment.
By end user, the independent reference laboratories segment is expected to be the fastest-growing end-user segment in the transplant diagnostics market during the forecast period.
The transplant diagnostics market is categorized by end users into hospitals & transplant centers, research laboratories & academic institutions, and independent reference laboratories. In 2025, the independent reference laboratories segment is expected to dominate the market. This segment's large share is largely attributable to the rapid modernization and automation of diagnostic laboratories, the increasing number of research and development activities outsourced by pharmaceutical and biotechnology companies to independent reference laboratories, and the growing consolidation of diagnostic laboratories in developed countries. Additionally, the rising global demand for infectious disease diagnosis and tissue typing during donor-recipient profiling and cross-matching, along with the growing number of organ transplantation procedures and the increasing establishment and accreditation of diagnostic laboratories in both emerging and developed countries, are further driving the growth of this segment.
North America is the largest regional market for transplant diagnostics.
The transplant diagnostics market is categorized by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. By 2025, North America is expected to lead the transplant diagnostics market. This dominance is largely due to the widespread availability of advanced transplant diagnostic technologies, well-established distribution channels, and significant public awareness of the clinical benefits of these diagnostic products in assessing risks for donors and recipients during transplantation procedures. Additionally, the ongoing expansion of molecular diagnostic applications, such as pathogen testing and cytological analysis, along with increasing awareness of the clinical advantages of genomic screening in transplantation, is further driving market growth in this region. Furthermore, rising public-private investment and funding for genome-based transplant diagnostic research, as well as government initiatives to promote the adoption of genome-based medical diagnostics, are contributing to the growth of the transplant diagnostics market in North America.
The major players operating in this market are Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMérieux (France), Becton, Dickinson and Company (US), Illumina, Inc. (US), DiaSorin S.p.A. (Italy), CAREDX, INC. (US), and Werfen (Spain), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Transplant Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
